4 research outputs found
Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer
The prognosis of patients with colorectal cancer (CRC) is assessed
through conventional clinicopathological parameters, which are not
always accurate. Members of the human kallikrein-related peptidases gene
family represent potential cancer biomarkers. The aim of this study was
to investigate the expression of human tissue kallikrein-related
peptidase 10 (KLK10) by immunohistochemistry in CRC, to correlate this
expression with various histopathological and clinical variables, and to
evaluate its significance as a predictor of disease outcome. KLK10
expression was evaluated by immunohistochemistry and a combined
expression score was calculated for each case based on intensity and
percentage of positivity. A statistically significant positive
association was observed between KLK10 and tumor stage and liver
metastases (p = 0.015 and p = 0.035, respectively). Paradoxically, a
negative association was observed between KLK10 and tumor grade (p =
0.009). Kaplan-Meier survival curves and univariate analysis showed that
both KLK10 expression and stage had statistically significant
correlations with disease-free survival (DFS) (p = 0.030 and p < 0.001,
respectively) and overall survival (p = 0.010 and p = 0.001,
respectively). Cox multivariate analysis showed that both KLK10
expression and stage were independent predictors of unfavorable DFS (p =
0.057 and p = 0.001, respectively) and overall survival (p = 0.009 and p
= 0.001, respectively). In conclusion, KLK10 immunostaining is an
independent prognostic marker in patients with CRC
The Immunohistochemical Expression of Growth Hormone–Releasing Hormone Receptor Splice Variant 1 Is a Favorable Prognostic Marker in Colorectal Cancer
Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 (P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan–Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC